Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression.
Ontology highlight
ABSTRACT: Irinotecan (CPT-11) is a first-line anti-colon cancer drug, however; CPT-11-induced toxicity remains a key factor limiting its clinical application. To search for clues to the mechanism of CPT-11-induced toxicity, metabolomics was applied using ultra-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight mass spectrometry. Intraperitoneal injection of 50 mg/kg of CPT-11 induced loss of body weight, and intestine toxicity. Changes in gallbladder morphology suggested alterations in bile acid metabolism, as revealed at the molecular level by analysis of the liver, bile, and ileum metabolomes between the vehicle-treated control group and the CPT-11-treated group. Analysis of immune cell populations further showed that CPT-11 treatment significantly dec
SUBMITTER: Fang ZZ
PROVIDER: S-EPMC4718832 | biostudies-literature | 2016 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA